Patents by Inventor Joan-En Chang-Lin

Joan-En Chang-Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8933120
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8933127
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20140256675
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: April 8, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8772338
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 8, 2014
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 8729125
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: May 20, 2014
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20140100287
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: December 9, 2013
    Publication date: April 10, 2014
    Applicant: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20140045773
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: September 11, 2013
    Publication date: February 13, 2014
    Applicant: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20140045939
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: September 11, 2013
    Publication date: February 13, 2014
    Applicant: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Biodegradable Intravitreal Tyrosine Kinase Implants
    Publication number: 20140031408
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: August 19, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Compositions and methods for the intraocular transport of therapeutic agents
    Patent number: 8637571
    Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: January 28, 2014
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
  • METHOD FOR DETERMINING OPTIMUM INTRAOCULAR LOCATIONS FOR DRUG DELIVERY SYSTEMS
    Publication number: 20140010823
    Abstract: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
    Type: Application
    Filed: August 29, 2013
    Publication date: January 9, 2014
    Applicant: Allergan, Inc.
    Inventors: Michael R. Robinson, Joan-En Chang-Lin, Devin F. Welty, Patrick M. Hughes, Scott M. Whitcup
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8586630
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: November 19, 2013
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 8569370
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Method for determining optimum intraocular locations for drug delivery systems
    Patent number: 8571802
    Abstract: A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Joan-En Chang-Lin, Devin F. Welty, Scott M. Whitcup, Patrick M. Hughes
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 8569367
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: October 29, 2013
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8524777
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 3, 2013
    Assignee: Allergan Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 8512738
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as posterior ocular conditions.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Joan-En Chang-Lin, Jane Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8409607
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: April 2, 2013
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Jeffery L. Edelman, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8404267
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: March 26, 2013
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. De Vries, Jeffery L. Edelman, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 8338479
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: December 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin